@article {B{\'e}nard2020.07.02.184093, author = {Alan B{\'e}nard and Anne Jacobsen and Maximilian Brunner and Christian Krautz and Bettina Kl{\"o}sch and Izabela Swierzy and Elisabeth Naschberger and Torsten Birkholz and Ixchel Castellanos and Denis Trufa and Horia Sirbu and Marcel Vetter and Andreas E. Kremer and Kai Hildner and Andreas Hecker and Fabian Edinger and Matthias Tenbusch and Enrico Richter and Hendrik Streeck and Marc M. Berger and Thorsten Brenner and Markus A. Weigand and Filip K. Swirski and Georg Schett and Robert Gr{\"u}tzmann and Georg F. Weber}, title = {Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections}, elocation-id = {2020.07.02.184093}, year = {2020}, doi = {10.1101/2020.07.02.184093}, publisher = {Cold Spring Harbor Laboratory}, abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. Here, we report that low plasma interleukin-3 (IL-3) levels were associated with increased severity and mortality during SARS-CoV-2 infections. IL-3 promoted the recruitment of antiviral circulating plasmacytoid dendritic cells (pDCs) into the airways by stimulating CXCL12 secretion from pulmonary CD123+ epithelial cells. This study identifies IL-3 as a predictive disease marker and potential therapeutic target for SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.}, URL = {https://www.biorxiv.org/content/early/2020/07/02/2020.07.02.184093}, eprint = {https://www.biorxiv.org/content/early/2020/07/02/2020.07.02.184093.full.pdf}, journal = {bioRxiv} }